Results for tag: "Pulmonary Fibrosis"

Pulmonary Fibrosis is a chronic lung disease characterized by the formation of scar tissue in the lungs, leading to difficulty breathing. It is a progressive and irreversible condition, and is the most common form of interstitial lung disease. Symptoms of Pulmonary Fibrosis include shortness of breath, dry cough, fatigue, and weight loss. Treatment options include oxygen therapy, pulmonary rehabilitation, and medications to reduce inflammation. In some cases, lung transplantation may be necessary. The Pulmonary Fibrosis market is a subset of the Pulmonary Medicine market, which includes treatments and services for a variety of respiratory conditions. Companies in the Pulmonary Fibrosis market include Boehringer Ingelheim, Gilead Sciences, and Vertex Pharmaceuticals, which are all involved in the development of treatments for the disease. Other companies in the market include AstraZeneca, GlaxoSmithKline, and Novartis, which are involved in the development of medications to treat Pulmonary Fibrosis. Show Less Read more